- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients | 1 | Oslo Børs | ||
| ONCOINVENT Aktie jetzt für 0€ handeln | |||||
| 05.03. | Oncoinvent ASA: Mandatory notification of trade | - | Oslo Børs | ||
| 27.02. | Oncoinvent ASA: Fourth Quarter 2024 Update and Results | 1 | Cision News | ||
| 27.02. | Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients | 1 | Cision News | ||
| 26.02. | Oncoinvent ASA: Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference | 221 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference... ► Artikel lesen | |
| 20.02. | Oncoinvent ASA: Invitation to Result Presentation Q4 2024 | 351 | PR Newswire | OSLO, Norway, Feb. 20, 2025 /PRNewswire/ -- In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:
Thursday... ► Artikel lesen | |
| 19.02. | Oncoinvent ASA to present at various conferences | - | Oslo Børs | ||
| 18.02. | Oncoinvent ASA: Registration of new share capital | - | Oslo Børs | ||
| 06.02. | Oncoinvent ASA: Last day of the subscription period in the subsequent offering | 1 | Oslo Børs | ||
| 04.02. | Oncoinvent ASA: Grant of share options - mandatory notification of trade | - | Oslo Børs | ||
| 23.01. | Oncoinvent ASA: Commencement of subscription period for subsequent offering | 2 | Oslo Børs | ||
| 22.01. | Oncoinvent ASA: Key information relating to subsequent offering | - | Oslo Børs | ||
| 22.01. | Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering | - | Oslo Børs | ||
| 10.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 10.01.2025 | 545 | Xetra Newsboard | The following instruments on XETRA do have their first trading 10.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.01.2025
Aktien
1 ES06445809T5 Iberdrola S.A. BZR
2... ► Artikel lesen | |
| 18.12.24 | Oncoinvent ASA: Financial calendar | 2 | Oslo Børs | ||
| 13.12.24 | Oncoinvent lists on Euronext Growth Oslo | 3 | Euronext | ||
| 13.12.24 | Oncoinvent ASA: First day of trading on Euronext Growth Oslo and publication of information document | 3 | Oslo Børs | ||
| 12.12.24 | Oncoinvent ASA: Notifiable transactions in connection with Private Placement | 1 | Oslo Børs | ||
| 05.12.24 | Oncoinvent ASA announces oversubscribed private placement | 372 | PR Newswire | OSLO, Norway, Dec. 5, 2024 /PRNewswire/ -- Oncoinvent ASA ('Oncoinvent' or the 'Company') is pleased to announce that it has today successfully completed the bookbuilding process for a private... ► Artikel lesen | |
| 04.12.24 | Oncoinvent ASA: Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities | 291 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has entered into an agreement with ARTBIO, a clinical-stage radiopharmaceutical... ► Artikel lesen |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| TEMPUS AI | 47,200 | 0,00 % | Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? | ||
| CG ONCOLOGY | 22,050 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,470 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 1,100 | 0,00 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,815 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 6,125 | +1,07 % | Evotec-Aktie: Kurs fällt ab (6,365 €) | Die Aktie von Evotec notiert am Mittwoch leichter. Zuletzt zahlten Investoren für die Aktie 6,37 Euro. An der Börse liegt das Wertpapier von Evotec derzeit im Minus. Das Papier verbilligte sich um 3... ► Artikel lesen | |
| BIONTECH | 84,90 | +2,97 % | wO Börsenlounge: Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg gegen Biontech | CureVac hat bestätigt, dass das Europäische Patentamt eine überarbeitete Version seines mRNA-Patents bestätigt hat. Die Entscheidung dürfte Auswirkungen auf den Prozess gegen Biontech haben. Die Aktie... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,630 | 0,00 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,095 | 0,00 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| ARCELLX | 60,70 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| IMMUNOVANT | 15,190 | 0,00 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 41,900 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,800 | 0,00 % | Cantor Fitzgerald maintains Overweight on Summit Therapeutics shares | ||
| BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen |
Das Unternehmen ONCOINVENT ASA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,18 % bei einem Aktienkurs von 0,147 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOINVENT ASA finden Sie auf Wallstreet Online.
